StockData
Estrella Immunopharma, Inc. logo

Estrella Immunopharma, Inc. (ESLAW) income statement

ESLAWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLA
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.06−0.00 (-2.08%)

Close on Nov 18, 2026Market cap $14.48MP/E –Yield –

Estrella Immunopharma, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2024
-447.6%

Financial strength

Current ratio
0.20
Debt to equity
–
Debt to assets
–
Cash to current liabilities
1.1%

Valuation

P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–

See a number that looks wrong?